The "Cell Therapy Human Raw Materials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has ...

Clinical and commercial quality controls are eased as the FDA looks to expedite therapy approvals in areas of unmet need.

Reducing manual touchpoints is an important part of supporting more consistent and scalable manufacturing processes.

Regulatory authorities emphasize integrated control strategies, but CAR-T specification setting requires balancing data rigor with regulatory flexibility.

FDA Commissioner Marty Makary called these changes “common-sense reforms” that could expedite the development of cell and ...

Lumacyte CEO on how real-time insight is driving down manufacturing failures and opening doors for more patients.

Pharma and advanced therapy manufacturing will only grow more complex in science, regulation, and global scale. But the ...

The "Cell Therapy Processing: Global Markets and Technologies" report has been added to ResearchAndMarkets.com's offering. The global market for cell therapy processing is estimated to grow from $2.7 ...

Cellares, the contract drugmaker known for its cell therapy factory-in-a-box, will expand its operations to Europe after ...

The first half of 2025 has been a notable one for Cellares. The cell therapy manufacturer operates its first commercial-scale Integrated Development and Manufacturing Organization Smart Factory in ...

Universal gene‑edited CAR‑T therapies turn donor T cells into off‑the‑shelf cancer treatments, cutting delays and costs while ...